Effect of repeated four-monthly albendazole treatments on malaria in pre-school children living in communities endemic for Ascaris lumbricoides: a double-blind placebo-controlled randomised trial

ISRCTN ISRCTN44215995
DOI https://doi.org/10.1186/ISRCTN44215995
Secondary identifying numbers N/A
Submission date
28/07/2008
Registration date
25/09/2008
Last edited
16/04/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Celia Holland
Scientific

Department of Zoology
The University of Dublin
Trinity College
Dublin
02
Ireland

Study information

Study designDouble-blind placebo-controlled randomised trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study objectivesDeworming does not increase the incidence of malaria or the frequency of malaria attacks in pre-school children.
Ethics approval(s)The Ethics and Research Committee of Obafemi Awolowo University Teaching Hospitals' Complex (Nigeria) gave approval on the 13th April 2006 (ref: ERC/2006/03/16)
Health condition(s) or problem(s) studiedMalaria, helminth parasitisation
InterventionThere were two groups: the treatment (albendazole) group and the placebo group. A dose of 200 mg (one tablet) of albendazole was given to children aged 1 year. A dose of 400 mg (two tablets) of albendazole was given to children aged 2, 3 and 4 years. Children who were in the placebo group and aged 1 year were given one placebo tablet and children aged 2, 3 and 4 years were given two placebo tablets.

Children were given treatment or placebo at baseline, 4, 8 and 12 months and then followed up for the last time at 14 months. Children in the placebo group were treated with albendazole at 14 months.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Albendazole
Primary outcome measure1. Incidence of malaria, measured at baseline and 4, 8, 12 and 14 months
2. Malaria attacks, measured at baseline and 4, 8, 12 and 14 months
3. Infection with soil-transmitted helminths, measured at baseline and 4, 8, 12 and 14 months
Secondary outcome measures1. Nutritional status, measured at baseline and 14 months
2. Haemoglobin, measured at baseline and 4, 8, 12 and 14 months
Overall study start date16/05/2006
Completion date22/08/2007

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit12 Months
Upper age limit59 Months
SexBoth
Target number of participants1055
Key inclusion criteriaPre-school children aged 12 - 59 months, either sex
Key exclusion criteria1. Severe anaemia less than 5 g/dl
2. Severe malaria
Date of first enrolment16/05/2006
Date of final enrolment22/08/2007

Locations

Countries of recruitment

  • Ireland
  • Nigeria

Study participating centre

Department of Zoology
Dublin
02
Ireland

Sponsor information

The University of Dublin (Ireland)
University/education

Trinity College
Dublin
02
Ireland

Website http://www.tcd.ie/
ROR logo "ROR" https://ror.org/05m7pjf47

Funders

Funder type

Government

Health Research Board (HRB) (Ireland)
Private sector organisation / Other non-profit organizations
Alternative name(s)
HRB
Location
Ireland

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article anthelmintic results 19/02/2009 Yes No